Pfizer/Medarex Antibody Collaboration Includes Cross-Licensing Of Melanoma Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Medarex expects cross-licensing anti-CTLA-4 products will enhance opportunities for future products by clearing up potential intellectual property issues. Pfizer will make up-front payments totaling $110 mil. to secure 50 antibody products over 10 years.